If you want to find out more information on DOVATO (dolutegravir/lamivudine) and receive updates, contact our team today. See full Indication, Boxed Warning & PI.

You are now leaving this site.

You are about to leave a ViiV Healthcare website. By clicking “Continue,” you will be taken to a website that is independent from ViiV Healthcare. The site you are linking to is not controlled or endorsed by ViiV Healthcare and ViiV Healthcare is not responsible for the content provided on that site.

Sign Up to Hear the Latest News and Updates

Thank You!

Your request has been submitted.

Go to Home

PMUS-DLLWCNT240073 January 2025

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at www.gsk.public.reportum.com or 1-877-844-8872, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

BIKTARVY and GENVOYA are trademarks of Gilead Sciences, Inc. All other trademarks are owned by or licensed to the ViiV Healthcare group of companies.

This site is funded and developed by ViiV Healthcare.
This site is intended for US healthcare professionals only.
©2025 ViiV Healthcare or licensor.
PMUS-DLLWCNT240055 February 2025
Produced in USA.

Sign Up to Hear the Latest News and Updates

Thank You!

Your request has been submitted.

INDICATION